Aileron Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aileron Therapeutics, Inc. - overview
Established
2005
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Aileron Therapeutics, Inc. focuses on advancing therapeutics for cancer and other diseases by developing innovative treatments that utilize a proprietary platform for drug design and delivery. Founded in 2005 and headquartered in Watertown, US, Aileron Therapeutics, Inc. specializes in innovative therapies for cancer treatment.
The company has undergone strategic funding rounds to support its growth, with the latest being a Private Placement in January 2021, where they raised USD 35. 90 mn. The firm has raised a total of USD 35. 90 mn across various funding initiatives since inception.
The CEO, Manuel Aivado, leads the company, which has engaged in 13 deals to date. Aileron Therapeutics is dedicated to the development of multi-pathway therapeutics aimed at treating cancer. The company's primary offering is a proprietary platform that enables the design of drugs targeting specific pathways in cancer biology, thereby aiming to improve therapeutic efficacy. Their clientele includes healthcare providers and pharmaceutical partners engaged in oncology.
In 2020, Aileron Therapeutics reported a revenue of USD 0 and an EBITDA of -USD 16. 16 mn. The company's revenue model emphasizes partnerships and the potential commercialization of its therapeutic products upon successful development and regulatory approval. Aileron Therapeutics plans to leverage its most recent funding round to advance its product pipeline, focusing on launching new therapies targeting cancer pathways.
The company aims to expand into European markets by 2023, enhancing its reach and impact. The USD 35. 90 mn raised in January 2021 will facilitate research and development efforts, supporting clinical trials and potential market entry.
Current Investors
Novartis Venture Fund, Apple Tree Partners, Lilly Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.aileronrx.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aileron Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (23,031,000) | (31,937,000) | (30,032,000) | (20,342,000) | (26,244,000) | (27,686,000) | - | - | - |
| Operating Income (USD) | (23,008,000) | (31,902,000) | (29,956,000) | (20,496,000) | (26,605,000) | (27,647,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (22,604,000) | (31,547,000) | (29,369,000) | (21,157,000) | (26,164,000) | (27,329,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - |
Aileron Therapeutics, Inc. - employee data
Aileron Therapeutics, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.